April 13, 2026
A New Jersey federal judge sided Monday with a special master's recommendations to nix some of the parallel claims from Mylan and retailers like Walgreens accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment.
March 03, 2025
Mylan and pharmaceutical wholesalers should be allowed to proceed with some, but not all, parallel claims accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment, a special master has recommended in New Jersey federal court.
November 22, 2021
Teva Pharmaceuticals has urged a New Jersey federal court to toss a suit from Mylan accusing the generic-drug giant of an illegal scheme to stifle competition to its multiple sclerosis treatment, arguing that Mylan is just misplacing blame for its own disappointment.